                         SEQUENCE LISTING

<110>  KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
       THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE 
       SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
 
<120>  CELL LINKERS FOR HETEROTYPIC CELL SPHEROIDS

<130>  Dkt No. 51074-PCT

<150>  US 62/698,602
<151>  2018-07-16

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic adhesion sequence

<400>  1

Tyr Ile Gly Ser Arg 
1               5   


<210>  2
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic spacer sequence

<400>  2

Ile Gly Pro Gly Gly Asp Gly Pro Gly Gly 
1               5                   10  


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic spacer sequence

<400>  3

Ile Gly Pro Gly Pro Gly Gly 
1               5           


<210>  4
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic spacer sequence

<400>  4

Gly Pro Gly Gly Asp Gly Pro Gly Gly 
1               5                   


<210>  5
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  5

Phe Leu Ile Tyr Ile Gly Ser Arg Ile Gly Pro Gly Gly Asp Gly Pro 
1               5                   10                  15      


Gly Gly Arg Gly Asp 
            20      


<210>  6
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  6

Phe Leu Ile Tyr Ile Gly Ser Arg Ile Gly Pro Gly Gly Asp Gly Pro 
1               5                   10                  15      


Gly Gly Lys Gly Asp 
            20      


<210>  7
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  7

Phe Leu Ile Tyr Ile Gly Ser Arg Ile Gly Pro Gly Gly Asp Gly Pro 
1               5                   10                  15      


Gly Gly Leu Asp Val 
            20      


<210>  8
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  8

Leu Asp Val Ile Gly Pro Gly Gly Asp Gly Pro Gly Gly Arg Gly Asp 
1               5                   10                  15      


<210>  9
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  9

Tyr Ile Gly Ser Arg Ile Gly Pro Gly Pro Gly Gly Arg Gly Asp 
1               5                   10                  15  


<210>  10
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  10

Arg Gly Asp Ile Gly Pro Gly Gly Asp Gly Pro Gly Gly Arg Gly Asp 
1               5                   10                  15      


<210>  11
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  11

Leu Asp Val Gly Pro Gly Gly Asp Gly Pro Gly Gly Arg Gly Asp 
1               5                   10                  15  


<210>  12
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  12

Phe Leu Ile Tyr Ile Gly Ser Arg Ile Gly Pro Gly Gly Asp Gly Pro 
1               5                   10                  15      


Gly Gly Tyr Ile Gly Ser Arg 
            20              


<210>  13
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide linker

<400>  13

Arg Gly Asp Ile Gly Pro Gly Gly Asp Gly Pro Gly Gly Leu Asp Val 
1               5                   10                  15      


<210>  14
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic hydrogel peptide

<400>  14

Phe Leu Ile Val Ile Gly Ser Ile Ile Gly Pro Gly Gly Asp Gly Pro 
1               5                   10                  15      


Gly Gly Asp 
            


